CASC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cascadian Therapeutics Inc's other long-term liabilities for the quarter that ended in Sep. 2016 was $0.17 Mil.
Cascadian Therapeutics Inc's quarterly other long-term liabilities declined from Mar. 2016 ($1.01 Mil) to Jun. 2016 ($0.26 Mil) and declined from Jun. 2016 ($0.26 Mil) to Sep. 2016 ($0.17 Mil).
Cascadian Therapeutics Inc's annual other long-term liabilities declined from Dec. 2013 ($1.10 Mil) to Dec. 2014 ($0.52 Mil) but then increased from Dec. 2014 ($0.52 Mil) to Dec. 2015 ($1.14 Mil).
Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Marts balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
Cascadian Therapeutics Inc Annual Data
|Other Long-Term Liab.||2.10||12.26||0.03||10.09||13.01||29.56||3.51||1.10||0.52||1.14|
Cascadian Therapeutics Inc Quarterly Data
|Other Long-Term Liab.||2.01||0.57||0.52||0.21||0.38||0.48||1.14||1.01||0.26||0.17|